AstraZeneca PLC [NASDAQ: AZN] jumped around 1.7 points on Friday, while shares priced at $53.07 at the close of the session, up 3.31%. The company report on May 1, 2021 that FARXIGA Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type 2 Diabetes.
Approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years.
In DAPA-CKD Phase III trial, FARXIGA demonstrated unprecedented reduction in the risk of the composite of worsening of renal function, end stage kidney disease and cardiovascular or renal death.
AstraZeneca PLC stock is now 6.16% up from its year-to-date (YTD) trading value. AZN Stock saw the intraday high of $54.5601 and lowest of $52.935 per share. The company’s 52-week high price is 64.94, which means current price is +14.18% above from all time high which was touched on 01/26/21.
Compared to the average trading volume of 10.56M shares, AZN reached a trading volume of 15298041 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about AstraZeneca PLC [AZN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AZN shares is $63.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AZN stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Argus have made an estimate for AstraZeneca PLC shares, keeping their opinion on the stock as Hold, with their previous recommendation back on April 12, 2021. The new note on the price target was released on March 16, 2021, representing the official price target for AstraZeneca PLC stock.
The Average True Range (ATR) for AstraZeneca PLC is set at 0.99, with the Price to Sales ratio for AZN stock in the period of the last 12 months amounting to 5.08. The Price to Book ratio for the last quarter was 8.92, with the Price to Cash per share for the same quarter was set at 3.13. Price to Free Cash Flow for AZN in the course of the last twelve months was 508.66 with Quick ratio for the last quarter at 0.80.
How has AZN stock performed recently?
AstraZeneca PLC [AZN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.55. With this latest performance, AZN shares gained by 6.74% in over the last four-week period, additionally plugging by 4.10% over the last 6 months – not to mention a rise of 1.51% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AZN stock in for the last two-week period is set at 62.61, with the RSI for the last a single of trading hit 65.47, and the three-weeks RSI is set at 59.85 for AstraZeneca PLC [AZN]. The present Moving Average for the last 50 days of trading for this stock 49.95, while it was recorded at 52.25 for the last single week of trading, and 52.71 for the last 200 days.
AstraZeneca PLC [AZN]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and AstraZeneca PLC [AZN] shares currently have an operating margin of +16.98 and a Gross Margin at +74.01. AstraZeneca PLC’s Net Margin is presently recorded at +11.58.
Return on Total Capital for AZN is now 14.29, given the latest momentum, and Return on Invested Capital for the company is 10.66. Return on Equity for this stock inclined to 23.36, with Return on Assets sitting at 5.24. When it comes to the capital structure of this company, AstraZeneca PLC [AZN] has a Total Debt to Total Equity ratio set at 130.46. Additionally, AZN Total Debt to Total Capital is recorded at 56.61, with Total Debt to Total Assets ending up at 30.54. Long-Term Debt to Equity for the company is recorded at 115.18, with the Long-Term Debt to Total Capital now at 49.98.
Reflecting on the efficiency of the workforce at the company, AstraZeneca PLC [AZN] managed to generate an average of $32,750 per employee. Receivables Turnover for the company is 5.35 with a Total Asset Turnover recorded at a value of 0.45.AstraZeneca PLC’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 1.00.
Earnings analysis for AstraZeneca PLC [AZN]
With the latest financial reports released by the company, AstraZeneca PLC posted 0.48/share EPS, while the average EPS was predicted by analysts to be reported at 0.44/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 9.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AZN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AstraZeneca PLC go to 19.10%.
Insider trade positions for AstraZeneca PLC [AZN]
There are presently around $20,858 million, or 15.90% of AZN stock, in the hands of institutional investors. The top three institutional holders of AZN stocks are: PRIMECAP MANAGEMENT CO/CA/ with ownership of 50,108,946, which is approximately -2.697% of the company’s market cap and around 0.50% of the total institutional ownership; WELLINGTON MANAGEMENT GROUP LLP, holding 48,587,986 shares of the stock with an approximate value of $2.58 billion in AZN stocks shares; and CAPITAL INTERNATIONAL INVESTORS, currently with $1.38 billion in AZN stock with ownership of nearly -11.148% of the company’s market capitalization.
Positions in AstraZeneca PLC stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 389 institutional holders increased their position in AstraZeneca PLC [NASDAQ:AZN] by around 56,790,240 shares. Additionally, 317 investors decreased positions by around 72,932,430 shares, while 135 investors held positions by with 263,310,702 shares. The mentioned changes placed institutional holdings at 393,033,372 shares, according to the latest SEC report filing. AZN stock had 129 new institutional investments in for a total of 13,976,163 shares, while 85 institutional investors sold positions of 3,845,185 shares during the same period.